Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
gptkb:edaravone
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C10H10N2O5S
|
| gptkbp:clinicalTrials |
Phase III
potential neuroprotective agent ALS_treatment included_in_ALS_treatment_guidelines |
| gptkbp:contraindication |
severe renal impairment
hypersensitivity to edaravone monitor for liver function |
| gptkbp:dosageForm |
solution
|
| gptkbp:drugInterdiction |
available online
excreted in urine may interact with other medications metabolized in liver rapid distribution |
| gptkbp:globalPresence |
limited to certain countries
|
| gptkbp:hasCapacity |
available through manufacturer
|
| gptkbp:hasPopulation |
adults
pediatric patients |
| gptkbp:healthcare |
important for efficacy
important for understanding treatment |
| https://www.w3.org/2000/01/rdf-schema#label |
Radicava
|
| gptkbp:impact |
14 days
10 days off |
| gptkbp:lastProduced |
2017
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Mitsubishi_Tanabe_Pharma_Corporation
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:Japan gptkb:South_Korea gptkb:United_States |
| gptkbp:offers |
varies by region
|
| gptkbp:operates_in |
N07XX12
|
| gptkbp:packaging |
vials
|
| gptkbp:relatedPatent |
neurodegenerative diseases
oxidative stress |
| gptkbp:research |
government and private sources
|
| gptkbp:researchAreas |
ongoing studies
|
| gptkbp:researchFocus |
long-term effects
combination therapies |
| gptkbp:route |
intravenous
|
| gptkbp:safetyFeatures |
recommended during treatment
|
| gptkbp:sideEffect |
headache
nausea skin rash elevated liver enzymes |
| gptkbp:storage |
room temperature
|
| gptkbp:triggerType |
antioxidant
|
| gptkbp:usedFor |
Amyotrophic_lateral_sclerosis_(ALS)
|
| gptkbp:weight |
250.26 g/mol
|